



REDEFINING COLORECTAL CANCER

May 2022



Current Listings:
OTCQB | CNBX

FORWARD LOOKING STATEMENT

This company presentation may include “forward-looking statements.” All forward-looking statements are subject to a number of risks, uncertainties and assumptions, and you should not rely upon forward-looking statements as predictions of future events. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “potential,” “predict,” “project,” “should,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Examples of forward looking statements contained in this presentation include, among others, statements regarding our ability to develop and commercialize RCC-33; our ability to develop other products in our pipeline; status, timing and results of preclinical studies and clinical trials; the potential benefits of RCC-33; the timing of seeking regulatory approval of RCC-33; our ability to obtain and maintain regulatory approval; our estimates regarding our capital requirements; our plans to develop and market RCC-33 and the timing of our development programs; our estimates of the size of the potential markets for RCC-33; sources of cash, including the proceeds from this equity issuance and contributions from other sources; the rate and degree of market acceptance of RCC-33; our intellectual property position; our ability to maintain and protect our intellectual property rights; our results of operations, financial condition, liquidity, prospects, and growth strategies; our spending of the proceeds from this offering; the industry in which we operate; and the trends that may affect the industry or us. This presentation discusses product candidates that are under pre-clinical study and clinical trial and that have not yet been approved for marketing by the Food and Drug Administration. No representation is made as to the safety or efficacy of these product candidates for the therapeutic use for which they are being studied. All forward-looking statements are based upon current estimates and expectations about future events and financial and other trends. There is no guarantee that future results, performance or events reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.


OUR MISSION

Redefine colorectal cancer by development of novel Neoadjuvant Cannabinoid Therapies to address the treatment needs of patients, and improving patient outcome



SUMMARY

- ✓ CNBX is an audited and reporting company traded on the OTCQB. Company is getting ready for Phase I/II (a) clinical studies and for an uplist to NASDAQ.
- ✓ CNBX is developing **CNBX® RCC-33** a novel early intervention neoadjuvant therapy for Colorectal Cancer, with a unique mechanism of action
- ✓ Drug-based therapies for colorectal cancer remains a **high unmet medical need**: 3rd most diagnosed & 2nd most lethal cancer worldwide; 150k new cases and 53k deaths in the US annually
- ✓ Clinical team including Senior Gastroenterologists and opinion leaders from the Sourasky Medical Center in Tel-Aviv
- ✓ First in class pipeline including treatments for colorectal polyps, additional cancers, and neuropsychiatric conditions involving synthetic cannabinoids and psychedelic inspired formulations



A hand is pointing at a medical scan on a monitor. The scan shows a cross-section of a brain with a central lesion. The background is a blurred image of a medical scan.


**\$17 B
Market**

The Global Colorectal Cancer Therapeutics market is projected to reach \$17B by 2027, from \$12.1B in 2020, at a CAGR of 4.9% during 2021-2027. (Market Watch)

COLORECTAL CANCER (CRC)

- 3rd most commonly diagnosed worldwide
- 1,849,518 new cases in 2018 worldwide
- 2nd most lethal cancer worldwide and in the US
- 880,792 deaths in 2018 worldwide
- 67% of treated patients survive 5 years or more
- The leading cause of cancer deaths in the U.S. among non-smokers.
- 150,000 new cases and over 50,000 deaths in the US annually

NEOADJUVANT THERAPY: STANDARD OF CARE



NEOADJUVANT THERAPY

// Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery. //

National Cancer Institute

Standard of Care: Neoadjuvant Chemotherapy, Radiotherapy & Chemoradiotherapy

Limitations:


- Mild to severe side effects
- Suppressed immune system
- Potential resistance of tumor residues to postoperative chemotherapy *

“

* nCRT increases ITGH and may result in the expansion of resistant tumor cell populations in residual tumors. ”

Frontiers in Oncology. 2019

The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity.



CNBX[®] RCC-33: IMPROVING STANDARD OF CARE

Neoadjuvant Cannabinoid Therapy: CNBX[®] RCC-33

- High efficacy in reducing tumor volume
- Potentially low side effects
- Early intervention
- Delay potential resistance of tumor residues to postoperative chemotherapy




CNBX[®] RCC-33

REDUCING TUMOR SIZE

33% reduction
in tumor volume on day 21

P-Value = 0.016


Effect of CNBX[®] RCC-33 on Tumor Development in Mice Inoculated with Human Colorectal Cancer Cell



27% reduction in tumor volume. P-Value = 0.022 (Day 17)

30% reduction in tumor volume. P-Value = 0.019 (Day 19)

33% reduction in tumor volume. P-Value = 0.016 (Day 21)



RCC-33: PROPOSED TREATMENT & OBJECTIVES

01

Intervene with RCC-33
during preoperative period

02

Obtain reduced **T** findings on TNM Staging:
lower tumor volume and tissue invasion

03


Obtain more favorable
Staging: increase stage II
group over stage III

04

Reduce postoperative cancer cell
resistance to chemotherapy


Proprietary First-in-class Synthetic Cannabinoids & Psychedelic Inspired Pipeline

Product/clinical path	Discovery	Preclinical		Clinical		
		In-vitro	In-vivo	Phase I	Phase II (a)	Comments
Colorectal Cancer						
CNBX® RCC-33 Colorectal Cancer					2023- 2025	Launch Phase I/II (a) by Q3 of 2023
CNBX® PLP-33 Pre-cancerous Polyps				2022-2024		Complete Phase I by end of 2024
Additional Cancers						
CNBX® MLN-33 Melanoma			2022-2023			Complete Pre-IND by end of 2023
CNBX® BRST-33 Breast Cancer			2022-2023			Complete Pre-IND by end of 2023
CNBX® PRST-33 Prostate Cancer			2022-2023			Complete Pre-IND by end of 2023
Neuropsychiatry						
NP-01	2022	[N/A]				Preclinical strategy TBD
NP-02	2022	[N/A]				Preclinical strategy TBD

 Completed

 Upcoming

FIRST-IN-CLASS IN-HOUSE DRUG DISCOVERY PLATFORM



Fully owned IP with Strong Patent Protection

Broad Claims including Pharmaceutical Composition

8 Patent Families		5 Granted 20 Pending	Pharmaceutical Composition	Methods and Systems
Patent Family	Patent Application No.	Directed to		Term
1	PCT/IL2016/050471	Personalized medicine for identifying antitumor effect of cannabis extracts		2036
2	PCT/IL2017/050231	Composition for treating cancer-related cachexia and anorexia syndrome (CACS)		2037
3	PCT/IL2018/050004	Sensitive testing of cannabinoids on tumor biopsies and circulating tumor cells (CTCs)		2038
4	US 2019/0134123	Microbiome profiling and modulation by cannabis		2039
5	PCT/IL2021/050419	Composition and method for treating cancer including colorectal cancer		2041
6	PCT/IL2021/050668	Compositions and methods for treating dysplastic and early stage neoplastic conditions		2041
7	US provisional No.: 63 / 255, 194	Cannabinoid compositions and methods for treating cancer		2042
8	US provisional No.: 63 / 255, 206	Cannabinoid Compositions and methods for treating early stage cancer		2042

*Major aspect of the invention is listed. Application may include other related aspects

**Patent term may be extended for a patent claiming a product or method that requires regulatory approval

Global Leader in AI-Based Discovery & Development of novel Synthetic Cannabinoid-based & Psychedelic inspired Medicines

Drug Discovery

Conduct all screening and pre-clinical research at in-house state of the art laboratory facilities

Intellectual Property

Expand and protect the technology, inventions, and trade secrets that are critical for business development



AI Based Bioinformatics

Leverage proprietary bioinformatics platform to develop novel cannabinoid formulations & research programs

Regulatory Affairs

FDA targeted Regulatory Affairs strategy & clinical development programs

Drug Candidates

LEADERSHIP

BOARD OF DIRECTORS

Gabriel Yariv

Executive Chairman of the Board

Mr. Yariv, 44, brings over 20 years of successful international leadership experience in the medical industry. Mr. Yariv is an accomplished entrepreneur having co-founded and managed several private and public companies in the Medical sector including Simutec Corp and BreathID Inc. (now Exalenz BioScience) inside Oridion Medical (now Medtronic).

Eyal Barad

Board Member

Mr. Barad serves also as CEO of CNBX Pharmaceuticals

DR. Gil Feiler

Independent Board Member, Audit & Compensation Committees

Dr. Feiler is a founding partner at Forest Investment House (\$1B AUM) with over 30 years of executive experience. Dr. Feiler also serves as a Director of several private and public companies.

DR. Inbar Maymon-Pomeranchik

Independent Board Member, Audit & Compensation Committees

Dr. Maymon-Pomeranchik brings nearly 20 years of executive level experience in biotech, with particular expertise in the global medical cannabis industry. Dr. Maymon-Pomeranchik also serves as a Director of several private and public companies.

Shaul Yemal

Independent Board Member, Head of Audit Committee

Mr. Yemal, brings decades of transnational management and finance experience. Mr. Yemal served as Senior Economist in the Division of Economic Consulting for the Ministry of Finance, Budget Division of the Minister of Finance and Manager of the Economic and Planning Division of the Ministry of Energy (Israel). Mr. Yemal was acting Chair of Financial, Auditor and Compensation Committees for numerous companies both public and private.

MANAGEMENT

Eyal Barad

Co-Founder & CEO

Mr. Barad, 56, brings over 30 years of successful international leadership experience. Mr. Barad was a pioneer in the digital publishing industry in NYC, and has been with Cannabics for 5 years where he led the company in its development of its core business along with a successful completion of several financing rounds in the capital markets.

Uri Ben-Or

CFO

Over 20 years of experience in corporate finance, accounting, M&A transactions, IPO's and operations.

LEADERSHIP

CLINICAL ADVISORY BOARD

Prof. Caroline Robert (MD)

Melanoma

Prof. Caroline Robert, M.D., Ph.D., is a world-renowned expert on Melanoma. She is Head of the Dermatology Unit at Institut Gustave Roussy in Paris, France.

Prof. Amos Toren (MD)

Oncology

Prof. Amos Toren is the Director of Pediatric Hemato- Oncology and BMT department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler school of medicine tel-aviv university.

Prof. Zamir Halpern (MD)

Gastroenterology

Prof. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel.

Prof. Noam Shomron (Ph.D.)

Big Data and AI

Professor Noam Shomron is passionate about using basic science to advance better healthcare. Professor Shomron heads the Functional Genomic Team at the Faculty of Medicine at Tel Aviv University, after training at MIT.

Dr. Yonina Tova (MD)

Oncology

Dr. Tova is an internationally recognized Radiation Oncologist. Dr. Tova is certified by the American Board of Radiology (ABR), and currently serves as Director of the Radiotherapy Institute at Ziv Hospital in Israel.

Dr. Sigal Tavor (MD)

Hematology

Dr. Tavor currently serves as a Senior Physician at the Hemato Oncology Institute, Assuta Medical Center, Tel-Aviv, Israel.

Dr. Erez Scapa (MD)

Gastroenterology

Dr. Scapa is a Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, who completed a Research Fellowship in Hepatology at the Brigham and Women's Hospital, Harvard University.

Dr. Dana Ben-Ami Shor (MD)

Gastroenterology

Dr. Ben-Ami Shor is a recognized expert in invasive endoscopy and gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel.

Dr. Sigalit Arieli Portnoy (Ph.D.)

Regulatory Affairs

Dr. Sigalit Arieli-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro Pharmaceutical Industries LTD as Operation Group Vice President and in Teva Pharmaceutical industries LTD as OSD plant manager.



3 Bethesda Metro Center
700 Bethesda, MD 20814
Phone: (877) 424-2429
info@cnbxpharma.com
www.cnbxpharma.com